Summary of Key Points Core Viewpoint - The Beijing Stock Exchange (BSE) has seen a decrease in trading volume and value over the past week, with a total of 266 listed companies and a total share capital of 37.067 billion shares as of June 8, 2025 [2][3]. Trading Activity - The weekly trading volume from June 2 to June 8 was 4.547 billion shares, a decrease of 28.37% compared to the previous week [3]. - The weekly trading value was 99.367 billion yuan, down 21.90% from the previous week [3]. - The average trading price increased by 9.04% to 21.85 yuan [3]. - The BSE 50 Index rose by 1.30% to 1427.06 points, with 28 stocks increasing, 1 remaining flat, and 21 declining [3]. New Listings and Applications - One company submitted a registration application and another had its listing application accepted during the week [5][9]. - As of June 8, 2024, there are 76 companies awaiting review, including 10 under "accepted," 56 under "inquiry," and 9 under "submitted for registration" [5]. - Three companies passed the counseling acceptance during the week [12]. Company Highlights - Hebei Shichang Automotive Parts Co., Ltd. plans to raise 171 million yuan for a new energy high-pressure oil tank project and working capital, with projected revenue growth of 22.05% in the first half of 2025 [8]. - Guangxi Senhe High-tech Co., Ltd. aims to raise 490 million yuan for an environmentally friendly precious metal extraction agent project, with revenue growth from 3.02 billion yuan in 2022 to 6.23 billion yuan in 2024 [11]. - Guangdong Banzhe Chuangke Electric Co., Ltd. passed counseling acceptance, reporting net profits of 108 million yuan and 148 million yuan for 2023 and 2024, respectively [13][14]. - Tianbo Information Technology Co., Ltd. also passed counseling acceptance, with net profits of 29.59 million yuan and 46.41 million yuan for 2023 and 2024 [15][16]. - Ying's Holdings Group Co., Ltd. reported net profits of 216 million yuan and 190 million yuan for 2023 and 2024, respectively, and passed counseling acceptance [17]. Counseling and Applications - Three companies entered the counseling period during the week [18]. - Two companies submitted counseling materials [25].

截至6月5日，北交所融资融券余额合计54.65亿元，较前一交易日增加9525.90万元，其中，融资余额 54.64亿元，较前一交易日增加9534.34万元，融券余额为99.78万元，较前一交易日减少8.44万元。 证券时报·数据宝统计显示，截至6月5日，北交所股票中，融资余额居前的为锦波生物、艾融软件、贝 特瑞，最新融资余额分别为3.46亿元、1.47亿元、1.40亿元，从最新融资余额占流通市值比例看，算术 平均值为1.11%，最新融资余额占流通市值比例居前的有美登科技、科力股份、派诺科技等，占比分别 为5.00%、4.22%、4.06%。 北交所股票中，6月5日共有158只股获融资净买入，净买入金额在百万元以上的有60只，吉林碳谷融资 净买入额居首，当日净买入876.89万元，其次是锦波生物、并行科技，融资净买入金额分别为660.19万 元、565.69万元，融资净买入金额居前的还有一致魔芋、富士达、森萱医药等。融资净卖出金额居前的 股票为诺思兰德、海希通讯、路斯股份等，融资净卖出金额分别为454.19万元、408.36万元、393.67万 元。 分行业统计，获融资净买入超百万元的北交所股票中，机械设备、计 ...

Core Viewpoint - The Beijing Stock Exchange and China Securities Index Co., Ltd. announced a regular adjustment of the sample stocks and reserve list for the Bei Zheng 50 Index (899050), effective June 16, 2025 [1] Group 1: Sample Stocks - The Bei Zheng 50 Index (899050) includes a total of 50 sample stocks, with notable companies such as: - Nuo Si Lan De (430047) - Hua Ling Co., Ltd. (430139) - Su Zhou Axle Co., Ltd. (430418) - Feng Guang Precision (430510) - An Da Technology (830809) [2] - Additional companies in the index include: - Sen Xuan Pharmaceutical (830946) - Chuang Yuan Xin Ke (831961) - Ao Di Wei (832491) - Na Ke Nuo Er (832522) - De Yuan Pharmaceutical (832735) [2][3] Group 2: Reserve List - The reserve list for the Bei Zheng 50 Index (899050) includes: - Jia Xian Co., Ltd. (920489) - Lei Shen Technology (872190) - Hui Feng Diamond (839725) - Lian Di Information (839790) - Yun Li Wu Li (872374) [3]

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2025-039 江苏森萱医药股份有限公司 关于完成注册地址变更并取得营业执照的公告 江苏森萱医药股份有限公司（以下简称"公司"）根据自身发展现状及未来 战略规划，对公司注册地址进行变更，具体变更情况如下： | 变更项目 | 变更前 | 变更后 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 注册地址 | 泰兴市虹桥镇中丹路西侧 | 南通市如东县洋口镇双墩路 | | | | 2 号 | | | | 听海轩 4 | 幢 | 7 | 层 | | 除注册地址发生变更外，其他工商信息未发生变更；公司办公地址未发生变 化，仍为江苏省南通市崇川区青年中路 198 号国城生活广场办公楼 A 幢 21 楼。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 一、基本情况 二、审议情况 本次注册地址的变更事项已经公司第四届董事会第八次会议及 2024 年年度 股东会审议通过。 三、工商登记情况 近日，公 ...

Investment Rating - The investment rating for the company is upgraded to "Outperform" [2] Core Views - The company reported a revenue of 537 million yuan in 2024, a year-on-year decline of 8.89%, with a net profit attributable to the parent company of 124 million yuan, down 8.00% year-on-year [2] - The company has increased its patent count to 192, with 42 invention patents, indicating a strong focus on research and development [3] - The company is implementing a strategy to refine its raw material drug structure, specialize in intermediates, and expand into new materials and innovative drugs [4] Financial Summary - The company achieved a revenue of 590 million yuan in 2023, with a projected revenue of 706 million yuan by 2027, reflecting a compound annual growth rate [5] - The gross profit margin is expected to remain stable around 43.4% to 43.9% from 2025 to 2027 [5] - The earnings per share (EPS) is projected to increase from 0.30 yuan in 2025 to 0.41 yuan in 2027 [5] Revenue and Profit Forecast - The forecast for net profit attributable to the parent company is adjusted to 130 million yuan for 2025, 153 million yuan for 2026, and 174 million yuan for 2027 [2][5] - The company anticipates a slight revenue increase in 2025, with a projected revenue of 544 million yuan, followed by a more significant growth in subsequent years [5] Market Position and Product Development - The company has successfully registered new raw materials in the European and American markets, which is expected to contribute to future revenue growth [3] - The production of the new raw material drug projects is underway, with a focus on expanding the product line [3]

Summary of Key Points Core Viewpoint - The Beijing Stock Exchange (BSE) has seen significant trading activity and new listings, indicating a growing market with increased investor interest and participation. Trading Activity - As of May 18, 2025, there are 266 companies listed on the BSE with a total share capital of 36.498 billion shares and a circulating share capital of 23.096 billion shares [2] - For the week of May 12 to May 18, the trading volume reached 8.072 billion shares, a week-on-week increase of 42.28%, while the trading amount was 173.488 billion yuan, up 39.35% from the previous week [3] - The average trading price during this period was 21.49 yuan, reflecting a decrease of 2.06% [3] - The BSE 50 Index rose by 3.13% to 1422.43 points, with 25 stocks increasing, none remaining flat, and 25 declining [3] New Listings - One company successfully listed on the BSE during the week, bringing the total to 266 [6] - Tian Gong Co., Ltd. (stock code: 920068) was the latest addition, listed on May 13, 2025, and is the first company to split from a Hong Kong stock to list on the BSE [7] - On its first trading day, Tian Gong's stock peaked with a 498.98% increase, closing at 20.17 yuan, a rise of 411.93% with a trading volume of 1.076 billion yuan [7] - As of May 19, 2025, Tian Gong's stock price reached 22.99 yuan, with a total market capitalization of 14.9 billion yuan, reflecting a 4.45% increase from its listing day [7] Upcoming Listings and Applications - As of May 18, 2024, there are 62 companies awaiting approval for listing on the BSE, including 5 under review, 48 in inquiry, and 8 submitted for registration [5] - One company, Youli Intelligent Equipment Co., Ltd. (stock code: 874325), passed the listing committee meeting during this period [12] - Youli Intelligent plans to raise 358 million yuan for the construction of a production base for photovoltaic support components and other projects [13] Financial Performance of Listed Companies - Tian Gong's revenue for 2022 to 2024 was 383 million yuan, 1.035 billion yuan, and 801 million yuan, with net profits of 70.31 million yuan, 175 million yuan, and 174 million yuan respectively [9] - For the first quarter of 2025, Tian Gong expects to achieve revenue of 192 million yuan [10] - Youli Intelligent's revenue for the same period was 433 million yuan, 658 million yuan, and 729 million yuan, with net profits of 42.19 million yuan, 78.17 million yuan, and 90.05 million yuan [14] Other Companies in the Pipeline - Several companies, including Yuelong Technology, Kelairedi, and Kanghua Co., have passed the counseling acceptance process, indicating their readiness for potential listing [20][21][24] - These companies are involved in various sectors, including medical devices, chemical pharmaceuticals, and tourism services, showcasing the diversity of industries represented on the BSE [24][26][27]

Investment Rating - The report maintains a positive outlook on the innovative drug sector within the healthcare industry [1]. Core Insights - The pharmaceutical sector outperformed the CSI 300 index slightly, with the Shenwan Pharmaceutical and Biological Index rising by 1.27% from May 12 to May 16, 2025, and by 2.48% year-to-date, ranking 11th among 31 Shenwan primary industry indices [1][12]. - The current valuation of the pharmaceutical sector stands at 26.80 times (TTM overall method, excluding negative values), with a premium of 141.06% compared to the CSI 300 index [15]. - The innovative drug segment is experiencing a pullback due to U.S. President Trump's announcement regarding drug price reductions, but the report suggests that the actual implementation of such policies will be challenging and will not significantly impact Chinese innovative drug companies' international expansion [3][20]. Summary by Sections 1. Market Review - The pharmaceutical sector's performance from May 12 to May 16, 2025, showed a 1.27% increase, outperforming the CSI 300 index by 0.15 percentage points [10]. - Year-to-date, the sector has increased by 2.48%, surpassing the CSI 300 index by 3.64 percentage points [12]. 2. Key Events - On May 12, 2025, President Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S., potentially lowering prices by 30% to 80% [19]. 3. Industry Perspective - The innovative drug sector is expected to continue as a key investment theme for 2025, with a focus on international expansion and emerging markets, particularly in companies like Kexing Pharmaceutical [4][21]. - The report highlights that the ongoing collection and procurement policies in various pharmaceutical fields are accelerating, with potential growth in segments like insulin and orthopedics [4][21].

Investment Rating - The report maintains a positive outlook on the innovative drug sector within the healthcare industry [1] Core Insights - The pharmaceutical sector outperformed the CSI 300 index slightly, with the Shenwan Pharmaceutical and Biological Index rising by 1.27% from May 12 to May 16, 2025, and by 2.48% year-to-date, ranking 11th among 31 Shenwan primary industry indices [1][12] - The current valuation of the pharmaceutical sector stands at 26.80 times (TTM overall method, excluding negative values), with a premium of 141.06% compared to the CSI 300 index [15] - The innovative drug segment is expected to continue as a key investment theme for 2025, driven by advancements in research and development, and the potential for international market expansion [4][21] Summary by Sections 1. Market Performance - The pharmaceutical sector showed a slight outperformance against the CSI 300 index, with a 1.27% increase during the specified week [10] - Year-to-date, the sector has increased by 2.48%, outperforming the CSI 300 by 3.64 percentage points [12] 2. Key Events - On May 12, 2025, U.S. President Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S., potentially decreasing prices by 30% to 80% [19] 3. Industry Perspective - The innovative drug sector is experiencing a pullback due to Trump's announcement regarding drug price reductions in the U.S. However, the report suggests that the actual implementation of such policies will be challenging and unlikely to significantly impact Chinese innovative drug companies' international expansion [20] - The report emphasizes that the future growth of Chinese innovative drug companies will rely heavily on entering international markets, particularly the U.S. [3][21] 4. Investment Recommendations - The report continues to favor innovative drugs, international expansion, and sectors where centralized procurement impacts are clearing, such as insulin and orthopedics [4][21] - Companies with a focus on emerging markets are highlighted as having significant growth potential [4]

这意味着，强制性国标实施后，所有的乘用车必须安装自动紧急制动系统（简称AEBS），中国市场汽 车大规模前装AEBS进入倒计时。据悉，AEBS主要由感知（传感器）、决策（中央处理器）和执行 （制动机构）三大模块构成，包括报警和紧急制动两大系统。国联民生证券表示，渗透率提升有望催化 投资机会，从产业链图谱来看，AEBS功能渗透率提升主要催化感知层中摄像头和毫米波雷达、决策层 和执行层的制动系统等标的充分受益。 16日，A股盘中弱势震荡整理，北证50指数逆市上扬；港股盘中走势疲弱，两大股指小幅走低。 具体来看，沪指盘中弱势下探，深证成指、创业板指盘中一度翻红。截至收盘，沪指跌0.4%报3367.46 点，深证成指微跌0.07%报10179.6点，创业板指跌0.19%报2039.45点，上证50指数跌0.86%，北证50指 数涨0.49%，沪深北三市合计成交11242亿元，较昨日减少逾660亿元。 场内约3000股飘红，汽车产业链股爆发，豪恩汽电20%涨停，亚太股份、路畅科技、万安科技等均涨 停；医药板块走高，森萱医药20%涨停，拓新药业、哈三联等连续两日涨停；可控核聚变概念拉升，中 洲特材、常辅股份盘中创出新高；人 ...

16日，A股盘中弱势震荡整理，北证50指数逆市上扬；港股盘中走势疲弱，两大股指小幅走低。 具体来看，沪指盘中弱势下探，深证成指、创业板指盘中一度翻红。截至收盘，沪指跌0.4%报3367.46点，深证成指微跌0.07%报10179.6点，创业板指跌0.19%报 2039.45点，上证50指数跌0.86%，北证50指数涨0.49%，沪深北三市合计成交11242亿元，较昨日减少逾660亿元。 场内约3000股飘红，汽车产业链股爆发，豪恩汽电20%涨停，亚太股份、路畅科技、万安科技等均涨停；医药板块走高，森萱医药20%涨停，拓新药业、哈三联等 连续两日涨停；可控核聚变概念拉升，中洲特材、常辅股份盘中创出新高；人形机器人概念再度活跃，兆丰股份、精锻科技等涨超10%；值得注意的是，多只强势 股持续受到资金追捧，如成飞集成（收获8连板，利君股份近8日斩获7个涨停板，中毅达3月以来已累计大涨超260%。而金融、酿酒等权重板块却集体回调。 港股方面，阿里巴巴、恒生银行、信义光能等跌超3%，绿茶集团上市首日跌逾12%；网易大涨约13%，地平线机器人涨超5%。 医药板块盘中发力走高，创新药、减肥药概念等表现亮眼。截至收盘，森萱医药 ...